A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522026-13-00

Acronym

P24-05

Enrollment

Registered

2025-12-16

Start date

2026-01-12

Completion date

Unknown

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive compulsive disorder

Brief summary

The primary efficacy endpoint is the change in the total score on the Yale-Brown ObsessiveCompulsive Scale Second Edition (YBOCS-II) at end of treatment.

Detailed description

Change in total score of the YBOCS-II at visits 3 and 4, Change in total score of Obsessive-Compulsive Inventory-Revised (OCI-R) at visits 3, 4 and 5, Change in global functioning responses as assessed on the Clinical Global Impressions – Change (CGI-C) scale, Change in total score of Montgomery and Asberg Depression rating scale (MADRS)

Interventions

DRUGMatching film-coated placebo tablet

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Change in total score of the YBOCS-II at visits 3 and 4, Change in total score of Obsessive-Compulsive Inventory-Revised (OCI-R) at visits 3, 4 and 5, Change in global functioning responses as assessed on the Clinical Global Impressions – Change (CGI-C) scale, Change in total score of Montgomery and Asberg Depression rating scale (MADRS)	—

Primary

Measure	Time frame
The primary efficacy endpoint is the change in the total score on the Yale-Brown ObsessiveCompulsive Scale Second Edition (YBOCS-II) at end of treatment.	—

Countries

Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026